$18.56
-0.68 (-3.53%)
Performance
1D
—
1W
—
1M
—
3M
-34.27%
6M
-38.13%
1Y
-33.71%
YTD
-31.21%
Open$19.60
Previous Close$19.24
Day High$19.68
Day Low$18.40
52W High$42.50
52W Low$20.27
Volume—
Avg Volume1.86M
Market Cap5.88B
P/E Ratio—
EPS$-1.56
SectorBiotechnology
Technical Indicators
Full analysis →
SMA 50
$25.57
Below
RSI (14)
21.6
Oversold
Analyst Ratings
Strong Buy
14 analysts
Price Target
+66.6% upside
Current
$18.56
$18.56
Target
$30.92
$30.92
$20.23
$30.92 avg
$48.05
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 396.63M | 1.64B | 1.52B |
| Net Income | -271,195,406 | 316.28M | 306.08M |
| Profit Margin | -68.4% | 19.3% | 20.1% |
| EBITDA | -247,584,132 | 415.16M | 429.14M |
| Free Cash Flow | — | 185.08M | 215.40M |
| Rev Growth | — | +14.2% | +10.8% |
| Debt/Equity | 0.79 | 0.26 | 0.28 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |